← FDA DRUG APPROVALS

FDA NDA · NDA017824

HALOG

Sponsor: SUN PHARM INDS INC

APPLICATION
NDA017824
TYPE
NDA
ORIGINAL APPROVAL
1977-06-15
LATEST ACTION
2004-09-29
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT
MARKETING STATUS
Discontinued

Products

HALOG · ReferenceDiscontinued
HALCINONIDE 0.1% · OINTMENT · TOPICAL

Approval history

2004-09-29Labeling · Supplement 24 · standardLetterAP
1990-06-29Manufacturing (CMC) · Supplement 23 · standardAP
1989-06-27Manufacturing (CMC) · Supplement 22 · standardAP
1987-11-03Manufacturing (CMC) · Supplement 21 · standardAP
1986-05-27Manufacturing (CMC) · Supplement 20 · standardAP
1985-07-29Manufacturing (CMC) · Supplement 19 · standardAP
1985-01-24Manufacturing (CMC) · Supplement 18 · standardAP
1984-11-13Manufacturing (CMC) · Supplement 17 · standardAP
1983-12-12Manufacturing (CMC) · Supplement 15 · standardAP
1982-12-02Labeling · Supplement 13AP
1981-02-26Manufacturing (CMC) · Supplement 14 · standardAP
1980-04-15Manufacturing (CMC) · Supplement 12 · standardAP
1980-02-13Manufacturing (CMC) · Supplement 11 · standardAP
1979-11-19Manufacturing (CMC) · Supplement 10 · standardAP
1979-04-17Manufacturing (CMC) · Supplement 9 · standardAP
1979-01-10Manufacturing (CMC) · Supplement 8 · standardAP
1978-08-09Manufacturing (CMC) · Supplement 7 · standardAP
1978-05-12Manufacturing (CMC) · Supplement 6 · standardAP
1978-02-08Manufacturing (CMC) · Supplement 5 · standardAP
1978-01-09Manufacturing (CMC) · Supplement 4 · standardAP
1977-08-24Manufacturing (CMC) · Supplement 3 · standardAP
1977-08-24Manufacturing (CMC) · Supplement 1 · standardAP
1977-08-24Manufacturing (CMC) · Supplement 2 · standardAP
1977-06-15Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →